Because of the rarity, heterogeneity and complex patient
management associated with rare conditions, creating a
pharmaceutical development programme for the treatment
of one of these diseases is challenging. With this feature,
Leslie Wetherell, Executive Director of Project Management
and Rare Disease Franchise Lead at Worldwide Clinical
Trials, explores the importance of patient and stakeholder
engagement in rare disease clinical research.

Comments are closed.

%d bloggers like this: